Roche Holding stock gains on Simcere deal and solid first half

Roche Holding stock is edging higher on September 3, 2026, after the group agreed to pay up to USD 1.5 billion for rights to a new antibody from Simcere, while first half 2026 revenue grew 6 percent and neurology drugs led the expansion.

Roche Holding stock (ISIN CH0012032048) is trading higher on September 3, 2026, with shares around 354.20 CHF on SIX Swiss Exchange, up about 1.4 percent intraday, while the Swiss SMI index hovers near 14,372 points according to market data from finanzen ch.

New Simcere antibody deal supports Roche pipeline

On September 3, 2026, several Swiss market reports highlighted that Roche has acquired from China based Simcere rights to an antibody targeting B cell mediated diseases, underscoring the group's focus on immunology and oncology innovation as reported by a Zurich market article on Zonebourse.

According to this report, Roche could pay up to 1.5 billion USD in total to Simcere for the antibody rights, combining upfront, milestone and potential royalty payments, a scale that illustrates how the company is willing to deploy capital to refresh its late stage pipeline in autoimmune and inflammatory conditions.

First half 2026 shows renewed growth momentum

For the first half of 2026, Roche's global pharmaceuticals division generated revenue of 23.63 billion Swiss francs, which corresponds to about 23.63 billion CHF and represents growth of 6 percent year on year, as summarized in a sector overview of leading pharmaceutical groups published on September 3, 2026 that cites the companys latest half year figures.

Within that total, neurology revenue reached 4.97 billion CHF in the first half of 2026, up 9 percent compared with the prior year period, driven mainly by multiple sclerosis therapy Ocrevus, which itself achieved global sales of 3.47 billion CHF in the same period, up 7 percent year on year based on the same data compilation.

The combination of overall 6 percent pharmaceutical revenue growth and faster 9 percent expansion in neurology suggests that Roche is successfully pivoting toward specialty indications with durable demand, which can help offset headwinds from biosimilar competition in some legacy oncology products.

Stock performance in the Swiss indices

Intraday on September 3, 2026, Roche shares were quoted around 354.10 CHF in the Swiss Large Cap Index environment, implying a gain of about 1.4 percent compared with the previous close and putting the stock among the stronger performers in the Swiss SLI basket, according to a midday index overview from finanzen ch.

The same overview shows a broader SMI level of about 14,366.59 points as of 12:22 on September 3, 2026, which means the index is advancing as well, but Roche slightly outperforms the headline Swiss benchmark on that midday snapshot.

Flagship neurology drug Ocrevus illustrates growth profile

One of the clearest examples of Roche's current growth engines is the neurology franchise, where Ocrevus, used for multiple sclerosis, delivered 3.47 billion CHF in global sales in the first half of 2026, up 7 percent versus the same period a year earlier, based on the referenced sector analysis data.

This growth rate is somewhat lower than the 9 percent increase for the overall neurology portfolio, suggesting that newer or smaller neurology products are expanding at double digit rates and contributing incrementally to the divisions 4.97 billion CHF first half 2026 revenue.

Roche Holding stock and investor view

With the shares trading at about 354.20 CHF as of midday on September 3, 2026 on SIX Swiss Exchange and up roughly 1.4 percent on the day, Roche Holding stock continues to be supported by a combination of mid single digit revenue growth in the first half of 2026 and pipeline building deals such as the up to 1.5 billion USD Simcere antibody transaction reported the same day.

Roche Holding key data

• Company: Roche Holding AG
• ISIN: CH0012032048
• Ticker: ROG
• Trading venue: SIX Swiss Exchange
• Price (as of September 3, 2026, 12:28): 354.20 CHF
• Sector / Industry: Health care / Pharmaceuticals and biotechnology
• Index membership: SMI / SLI